Abstract

Antimicrobial stewardship programs (ASPs) in hematological patients are especially relevant. However, information about ASPs in this population is scarce. For 11 years, we quarterly assessed antimicrobial consumption and incidence and death rates of multidrug-resistant (MDR) bloodstream infections (BSI) in the hematology Department. Healthcare activity indicators were also monitored yearly. We performed an interrupted time-series analysis. Antimicrobials showed a sustained reduction with a relative effect of −62.3% (95% CI −84.5 to −40.1) nine years after the inception of the ASP, being especially relevant for antifungals (relative effect −80.4%, −90.9 to −69.9), quinolones (relative effect −85.0%, −102.0 to −68.1), and carbapenems (relative effect −68.8%, −126.0 to −10.6). Incidence density of MDR BSI remained low and stable (mean 1.10 vs. 0.82 episodes per 1000 occupied bed days for the pre-intervention and the ASP period, respectively) with a quarterly percentage of change of −0.3% (95% CI −2.0 to 1.4). Early and late mortality of MDR BSI presented a steady trend (quarterly percentage of change −0.7%, 95% CI −1.7 to 0.3 and −0.6%, 95% CI −1.5 to 0.3, respectively). Volume and complexity of healthcare activity increased over the years. The ASP effectively achieved long-term reductions in antimicrobial consumption and improvements in the prescription profile, without increasing the mortality of MDR BSI.

Highlights

  • The mean consumption of all antimicrobials decreased from 148.2 ± 16.2 defined daily doses (DDD) per 100 occupied bed days (OBD) in the pre-intervention period to

  • The interrupted time-series (ITS) analysis (Table 1, Figures 1–3) showed a sustained reduction in favor of the intervention with a relative effect of −62.3% (95% confidence interval [CI] −84.5 to −40.1) nine years after the inception of the Antimicrobial stewardship programs (ASPs), when compared with the expected antimicrobial consumption based on the pre-intervention trend

  • A decreasing trend with a change in slope of −3.32 DDD per 100 OBD

Read more

Summary

Introduction

In hematological patients receiving immunosuppressive therapy, collateral damages of antimicrobial consumption, especially broad-spectrum antibiotic therapy, include the selection of multidrug-resistant (MDR) microorganisms [2], an increased propensity to fungal infections [3], and microbiota dysbiosis [4]. Due to these reasons the impact of ASPs in patients with hematological diseases might be especially relevant, information regarding the development of antimicrobial stewardship strategies in these patients is scarce [5,6,7]. This program covers the entire hospital and presents specific interventions focused on hematological patients

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call